Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform Maculus Therapeutix Feb 19, 2021 07:00 HKT/SGT Read More
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma Eisai Feb 15, 2021 10:07 HKT/SGT Read More
エーザイとMSD、「レンビマ(R)」と「キイトルーダ(R)」の併用療法が進行性腎細胞がんの一次治療として、対照薬のスニチニブに対して、無増悪生存期間および全生存期間の有意な改善を示す Eisai Feb 15, 2021 09:00 JST Read More
Suntrap Discovered 'LeSoleil' for COVID-19 and the Epidemic Suntrap Life Technologies Ltd Feb 14, 2021 20:00 HKT/SGT Read More
Cofttek, China's Largest Manufacturer of PEA, Draws Attention of Investors Cofttek Holding Limited Feb 14, 2021 01:00 HKT/SGT Read More
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa Apollomics, Inc. Feb 12, 2021 13:00 HKT/SGT Read More
Novamind Announces Strategic Investment in Bionomics to Support PTSD Clinical Trial Novamind Inc. Feb 11, 2021 21:00 HKT/SGT Read More
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater China Apollomics, Inc. Feb 11, 2021 11:00 HKT/SGT Read More
APOLLOMICS(冠科美博)从ITERION THERAPEUTICS引进TEGAVIVINT Apollomics, Inc. Feb 11, 2021 11:00 HKT/SGT Read More
APOLLOMICS(冠科美博)從ITERION THERAPEUTICS引進TEGAVIVINT Apollomics, Inc. Feb 11, 2021 11:00 HKT/SGT Read More
APOLLOMICS(冠科美博)从EDISON ONCOLOGY引进一款创新实体瘤酪氨酸蛋白激酶抑制剂 Apollomics, Inc. Feb 10, 2021 10:12 HKT/SGT Read More
APOLLOMICS(冠科美博)從EDISON ONCOLOGY引進一款創新實體瘤酪氨酸蛋白激酶抑制劑 Apollomics, Inc. Feb 10, 2021 10:11 HKT/SGT Read More
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors Apollomics, Inc. Feb 10, 2021 10:10 HKT/SGT Read More